Astellas set to open new life sciences facilities in Cambridge, Massachusetts
Betsy Goodfellow | August 10, 2023 | News story | Business Development | Astellas Pharma, Pharmacy, pharmaceutical, science facility
On 9 August 2023, Astellas Pharma announced its plans to open what it has described as a “state-of-the-art life sciences facility” in DivcoWest’s Cambridge Crossing neighborhood; the facility will be located at 441 Morgan Avenue in Cambridge, Massachusetts, US.
The investment will be a demonstration of the company’s devotion to expanding its research and development footprint.
Tadaaki Taniguchi, chief medical officer at Astellas, commented: “This investment in Cambridge represents a significant milestone for Astellas, enabling us to continue growing our presence in the Greater Boston area and to create additional hubs for innovation and collaboration. We view this as a strategic approach to enhance our ways of working, foster new collaborations and open up new opportunities in the biopharma ecosystem. We look forward to leveraging the vibrant life sciences ecosystem in the area to drive scientific advancements that ultimately lead to better outcomes for patients.”
The establishment will be designed by Ennead and Jacobs Consulting and will have a view of the Charles River. When finished, there will be five outdoor terraces, direct access to a five-acre park, three underground parking levels, a bike room and much more. Astellas plans to have two floors occupied by 2024, equaling around 62,000 square feet.
The managing director at DivcoWest, Mark Roopenian, stated: “We are thrilled to welcome Astellas to Cambridge Crossing. Through thoughtful and purposeful design, CX has become home to some of the world’s leading life science and biotech companies offering both the built environment forward-thinking companies need for today’s research and development, and the vibrant community employees desire. We look forward to Astellas being part of the neighborhood and a collaborative partner.”
Rebecca Lee
Related Content
The Pharma Files: With Colin Williams from Astellas Pharma
Pharmafile chats with Colin Williams, Head of Marketing Excellence, Global Capabilities, Learning & Development at …
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return …
FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products
This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing …
